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RegulationPlant molecular farming (PMF) is a new branch of plant biotechnology, where plants are engineered to
produce recombinant pharmaceutical and industrial proteins in large quantities. As an emerging subdivision
of the biopharmaceutical industry, PMF is still trying to gain comparable social acceptance as the already
established production systems that produce these high valued proteins in microbial, yeast, or mammalian
expression systems. This article reviews the various cost-effective technologies and strategies, which are
being developed to improve yield and quality of the plant-derived pharmaceuticals, thereby making plant-
based production system suitable alternatives to the existing systems. It also attempts to overview the
different novel plant-derived pharmaceuticals and non-pharmaceutical protein products that are at various
stages of clinical development or commercialization. It then discusses the biosafety and regulatory issues,
which are crucial (if strictly adhered to) to eliminating potential health and environmental risks, which in
turn is necessary to earning favorable public perception, thus ensuring the success of the industry.be).
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Plant molecular farming (PMF) refers to the production of
recombinant proteins (including pharmaceuticals and industrial
proteins) and other secondary metabolites, in plants. This involves
the growing, harvesting, transport, storage, and downstream proces-
sing of extraction and purification of the protein (Wilde et al., 2002).
This technology hinges on the genetic transformability of plants,
which was first demonstrated in the 1980s (Bevan et al., 1983). The
first recombinant plant-derived pharmaceutical protein (the human
growth hormone) and the first recombinant antibody (expressed in
the progeny of the cross of two individual transgenic plants
expressing single immunoglobulin gamma and kappa chains) were
produced in transgenic plants in 1986 and 1989, respectively (Hiatt
et al., 1989; Barta et al., 1986). However, it was not until 1997 that the
first recombinant protein, avidin (an egg protein) was expressed in
transgenic maize for commercial purpose (Hood et al., 1997). These
exploits really demonstrated that plants could be turned into bio-
factories for the large scale production of recombinant proteins. It has
been proven over the years that plants have the ability to produce
even more complex functional mammalian proteins with therapeutic
activity, such as human serum proteins and growth regulators,
antibodies, vaccines, hormones, cytokines, enzymes and antibodies
(Liénard et al., 2007). This has been possible due to their ability to
perform post-translational modifications that make these recombi-
nant proteins fold properly and maintain their structural and
functional integrity.
The fast-growing market for recombinant biopharmaceuticals,
which accounted for about 10% of the pharmaceutical market in 2007
(Lowe and Jones, 2007), had been predicted to expand to US $
100 billion in 2010 (Knäblein, 2005). With increasing demand for bio-
pharmaceuticals, coupled with the high costs and inefficiency of the
existing production systems (Knäblein, 2005), which include yeast,
microbes, animals cells (Jones et al., 2003) and transgenic animals
(Harvey et al., 2002), there now exists a shortage in manufacturing
capacity, to such an extent that some patients have to wait for these
products. Hence transgenic plants are gaining more attention as the
new generation bio-reactors; with active research and development
activity in PMF identified in over one hundred and twenty companies,
universities, and research institutes, around the world (Basaran and
Rodríguez-Cerezo, 2008). The weightier advantages of the plant-
based system over the existing systems are the incentives for this. This
review also discusses the different technologies and the limitations of
the plant system with respect to the various approaches being
pursued to overcome the challenges in other to increase its social
acceptability. It also attempts to give an overview of the plant-derived
proteins and discusses the biosafety and regulatory issues of these
emerging technologies.2. Plant transformation strategies
2.1. Stable nuclear transformation
Stable nuclear transformation involves the incorporation of a
foreign gene or genes (exogenous) of interest into the nuclear
genome of the plant, thereby altering its genetic makeup, and leading
to the expression of the transgene after integration with the host
genome, thereby conferring stably inheritable traits that were not
present in the untransformed host plant. As the most common
method, stable nuclear transformation has produced most of therecombinant proteins till date. The method has been used to
accumulate protein in the dry seeds of cereals, which allows long-
term storage of the seed at room temperature without degradation of
the protein (Horn et al., 2004). Additionally, the system has high
scale-up capacity, as crops such as the cereals are grown practically
everywhere. However, a long production cycle of some crops and the
potential to cross with native species or food crops are limiting public
acceptance of this method (Commandeur et al., 2003).
2.2. Stable plastid transformation
Plastid transformation provides a valuable alternative to nuclear
transformation because it combines numerous advantages that the
nuclear transformation lacks, including the provision of a natural
biocontainment of transgene flow by out-crossing (as plastids are
inherited through maternal tissues in most species and the pollen
does not contain chloroplasts, hence the transgene may not be
transferable, thereby allaying public concerns (Cardi et al., 2010;
Meyers et al., 2010). Transgenic plants with homoplastomic chloro-
plast transformation (in which every chloroplast carries the trans-
gene) are selected after several generations of plant regeneration
from bombarded leaf explants, on selection medium containing
spectinomycin or in combination with streptomycin. Our group
(Reddy et al., 2002; Sadhu and Reddy, 2003) had previously achieved
accumulation of a bacterial- and a human therapeutic protein, up to
3–6% of total soluble proteins in tobacco chloroplasts. Recently, Oey
et al. (2009) reported a whopping expression level (70% of the total
soluble proteins) for a proteinaceous antibiotic, with the chloroplast
system, which represents the highest recombinant protein accumu-
lation achieved so far in plants. This enormous potentials notwith-
standing, plastid transformation is still limited in its applications, in
that even though it has been achieved in other plant species such as
tomato, eggplant, lettuce, and soybeans (Bock, 2007; Singh and
Verma, 2010), routine chloroplast transformation is only possible in
tobacco, which is inedible and highly regulated, being rich in toxic
alkaloids. It is also envisaged that protein stability will change over
time even with refrigeration (Horn et al., 2004).
2.3. Plant cell-suspension cultures
Plant cell-suspension culture is an alternative plant-based pro-
duction platform to mammalian cells for production of biopharma-
ceutical. The system guarantees sterile in vitro conditions, coupled
with high-level containment (Franconi et al., 2010) (ideal for
production of high purity pharmaceuticals) and cheaper and simpler
downstream processing and purification (Kim et al., 2008). Addition-
ally, the use of suspension cultured cells as expression system could
reduce heterogeneity of the protein and of the N-glycan, owing to the
uniformity in the size and type of cells (Liénard et al., 2007; De
Muynck et al., 2009). Moreover, the system is rapid, because there is
no need to regenerate and characterize transgenic plants, such that
productive cell lines can be generated within a few months (Shaaltiel
et al., 2007; Aviezer et al., 2009 ). Examples of plant suspension
culture-produced biopharmaceuticals include Dow Agroscience's
purified injectable Newcastle disease virus (NDV) vaccine for
chickens, which has been approved by the USDA Center for Veterinary
Biologics (http://www.dowagro.com/animalhealth) and Protalix's
recombinant human glucocerebrosidase for the treatment of Gaucher's
disease (http://www.protalix.com, Shaaltiel et al., 2007). Though
cheaper, safer, easier to manipulate and more rapid than most
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production platform the plant systemdoes offer, as the overall yield and
usability is somewhat limited by the diminishing level of recombinant
protein during the late stationary phase due to increased proteolytic
activity (Corrado and Karali, 2009). Besides, the system is still limited to
small number ofwell-characterizedplant cell lines (suchas tobacco, rice
carrot, or Arabidopsis) (Breyer et al., 2009).
2.4. Transient expression systems
The transient production platform is perhaps the fastest and the
most convenient production platform for plant molecular farming
(Rybicki, 2010). The systems, which are mainly used for quick
validation of expression constructs, are now being used routinely for
the production of considerable amounts of proteins within a few
weeks (Vézina et al., 2009). These include the following methods.
2.4.1. Agroinfiltration method
The agroinfiltration method, which was developed by Kapila et al.
(1997), involves infiltration of a suspension of recombinant Agrobac-
terium tumefaciens into tobacco leaf tissue, which facilitates the
transfer of T-DNA to a very high percentage of the cells, where it
expresses the transgene at very high levels without stable transfor-
mation, as in the case of transgenic crops. This method has now been
developed into a very rapid, high-yielding transient expression
strategy for producing clinical grade bio-pharmaceuticals (Vézina
et al., 2009; Pogue et al., 2010; Regnard et al., 2010).
2.4.2. Virus infection method
The virus infection method is dependent on the ability of plant
viruses such as tobacco mosaic virus (TMV) and potato virus X (PVX)
to be used as vectors to deliver foreign genes into plants, without
integration (Porta and Lomonossoff, 2002). Both expression platforms
infect tobacco plants and then transiently express a target protein in
the plant tissue. Meanwhile, Varsani et al. (2006) were able to
successfully obtain protein yield as high as 17% of the total protein,
using this expression method. However, as with other fresh plant-
based production systems, the recombinant protein has to be
processed immediately to prevent tissue degradation and of course
protein instability. This represents the only minor drawback of this
system. Nonetheless, a pharmaceutical company, Large Scale Biology
Corporation has adopted the system for the production of idiotype
vaccines for the treatment of B-cell non-Hodgkin's lymphoma, which
have successfully passed the phase I clinical testing (McCormick et al.,
2008).
2.4.3. The magnifection technology
Both the viral vector-based expression system and Agrobacterium-
mediated method are limited in their inability to achieve high-level
co-expression of two or several polypeptides necessary for the
assembly of heterooligomeric proteins (Giritch et al., 2006). Hence
the evolution of a new robust transient expression system known as
MagnICON®technology, which was developed by Icon Genetics, by
removing the coat protein (responsible for systemic movement) of
the noncompeting virus strains and the systemic delivery of the
resulting viral vectors to the entire plant using Agrobacterium as the
vehicle of delivery and primary infection (Gleba et al., 2005). This
method has not only improved infectivity but also remarkably
enhanced amplification and ultimately lead to high-level co-expres-
sion of several polypeptides, which were able to assemble functional
heterooligomeric proteins at much increased levels up to 100-fold,
including a full sized IgG (Giritch et al., 2006) and Yersinia pestis
antigens fusion protein F1–V (Rosales-Mendoza et al., 2010).
Other advanced viral vectors are currently being designed by
various platforms such as, Icon Genetics, Kentucky BioProcessing,
Fraunhofer, and host of others, to facilitate ease of manipulation,wider host range, speed, safety, low cost and high quality and yield of
pharmaceutical proteins required for clinical development (http://
www.kbpllc.com, Komarova et al., 2010; Pogue et al., 2010; Rybicki,
2009).
3. Limitations and optimization of plant production systems
In spite of the vast advantages of the plant production systems
over the established systems (Buonaguro and Butler-Ransohoff, 2010;
Obembe, 2010), there exist however, some limitations that make
them have comparatively lower social acceptance. The problem of low
yield (which can result from low-level transcript expression or the
instability of the recombinant protein) and non-mammalian glyco-
sylation are the two major challenges that militate against the full
exploitation of plants as alternative bioreactors to the mammalian cell
culture, especially. The challenge of choosing the most suitable host
plant for any specific biomolecule as well as downstream processing is
also being given due attention.
3.1. The problem of low yield
3.1.1. Optimizing transcript expression
In order to optimize transcript expression, the general strategy is
the use strong and constitutive promoters, such as the cauliflower
mosaic virus 35S RNA promoter (CaMV 35S) and maize ubiquitin-1
promoter (ubi-1), for dicots and monocot, respectively (Fischer et al.,
2004). Organ- and tissue-specific promoters are also being used to
drive expression of the transgenes (vaccine antigen HBsAg M, murine
single chain variable fragment (scFv) G4 and human interferon-α) in
the tissue or organ like the tuber, the seed and the fruit (He et al.,
2008; De Jaeger et al., 2002; Masumura et al., 2006). This tissue-
specific expression therefore prevents accumulation of the recombi-
nant protein in the vegetative organs, which might negatively affect
plant growth and development. Additionally, inducible promoters,
whose activities are regulated by either chemical or external stimulus,
may equally be used to prevent the lethality problem (Corrado and
Karali, 2009), as it is being used in cell suspension cultures (Nara et al.,
2000; Peebles et al., 2007). Besides, transcription factors can be used
as boosters for the promoters to further enhance the expression level
of the transgenes (Yang et al., 2001). Moreover, it has been recently
found that the terminator of the heat-shock gene of Arabidopsis
thaliana shows an increase in transcription of a foreign gene by four
times (Nagaya et al., 2010).
Furthermore, the expression constructs can also be designed to
ensure transcript stability and translational efficiency. This involves,
for instance, the removal of the native 5′ and 3′ untranslated regions
from the foreign gene and introducing 5′ untranslated leader
sequence of the tobacco mosaic virus RNA, rice polyubiquitin gene
RUB13, alfalfa mosaic virus or tobacco etch virus in the expression
construct, all of which have been separately shown to significantly
enhance the expression levels of transgenes (Lu et al., 2008; Sharma
et al., 2008). In addition to these leader sequences, the expression
cassette design can be such that the false AU-rich sequences in the 3′
untranslated regions that may act as splice sites are removed or
modified, to ensure transcript stability (Mishra et al., 2006). Besides,
the transcript stability can be ensured by co-expressing the gene of
interest and a suppressor of RNA silencing (Voinnet et al., 2003). It is
also established that each organism exhibits biased codon usage, such
that it might be important to adapt the coding sequence of the
heterologous gene to that of the host plant in order to optimize
translation efficiency (Liénard et al., 2007; ). In this regard, the
translational start-site of the heterologous protein is modified to match
with the Kozak consensus for plants (Kawaguchi and Bailey-Serres,
2002) or by using the sequence GCT TCC TCC after initiation codon, or
ACC or ACA before it (Sharma and Sharma, 2009). The codon
modification, however, should be empirically determined rather than
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in the same system, using the same construct (Rybicki, 2009). To this
end, codon combinations (A/G)(a/c)(a/g) AUG and (A/G)(u/C)(g/C)
AUG have been reported to be optimum for enhanced translational
activity in Arabidopsis and rice, respectively (Sugio et al., 2010). This
variation in the expression of the transgene may be due to position
effect, copy number of the transgene or gene silencing. With respect
to position effect, expression cassettes can now be designed to
contain the nuclear matrix attachment regions (MAR), which are
regulatory sequences that ensure the placement of the transgene in
suitable regions for mobilizing transcription factors to the promoters
(Streatfield, 2007). Besides, the problem of position effect can be
avoided by targeting the transgene into the plastids (Cardi et al.,
2010). For optimizing the generation of single-copy transgenics, the
strategies that have been used include the use of specific genetic
elements, including the cAMP response elements (CREs), for co-
transfer with transgene in the T-DNA (De Paepe et al., 2009).
Additionally, a new technology, which consists in the construction of
genetically autonomous artificial minichromosomes has been de-
scribed as providing infinite possibilities with several enormous
advantages including gene stability; owing to the absence of gene
silencing and position effect (Ananiev et al., 2009).
3.1.2. Optimizing protein's stability
For optimizing the stability of recombinant protein, which has
been considered as the single most important factor limiting the
yields inmolecular farming (Schillberg et al., 2005) certain subcellular
targeting might be needed. Not only does subcellular targeting
enhance protein stability, but it also determines the type of the
associated protein processing, and by adding fusions and affinity tags,
it can be used to improve downstream processing of isolation and
purification (Fischer et al., 2004). Proteins can be targeted to the
secretory pathway by an N-terminal signal peptide, which is cleaved
off for the release of the protein into the endoplasmic reticulum (ER).
Nonetheless, full-size immunoglobulins that are addressed to the
secretory pathway have been shown to accumulate at higher levels
and easily recovered when fused with to a stabilizing partner
(Benchabane et al., 2008; Floss et al., 2009). Most plant-derived
recombinant proteins produced so far have been secreted into the
apoplastic space of the cell wall (Streatfield, 2006), and have been
reported to accumulate at levels up to 100-fold greater than in the
cytosol (Schillberg et al., 1999). Recent evidence however suggests
that the tomato cathepsin D inhibitor (SlCDI) has the potential to be
used as an in-built protein-stabilizing agent for the protection of
cytosol-targeted recombinant proteins in plants (Goulet et al., 2010).
The stability and accumulation of recombinant protein could be
further increased by targeting to and retaining in other subcellular
compartments of the secretory pathways, such as the ER (Conrad and
Fiedler, 1998). This is accomplished by appending of SEKDEL ER
retention signal to the C-terminus of the protein (Rademacher et al.,
2008) or by using the N- or C-terminus fusion of γ-zein signal, which
has been found to be more efficient and more economical for
production of recombinant proteins (Mainieri et al., 2004; Torrent
et al., 2009a, 2009b).
Proteins that do not require post-translational modification like
glycosylation for their activity can be targeted to the chloroplast, or
better still the foreign gene can be used to transform chloroplast
directly, with highly enhanced protein accumulation. Moreover, post-
translational modifications of the ER lumen can also be avoided by
expressing the protein as translational fusion with oleosin protein,
which target the expression of the foreign protein to oil bodies of the
seeds (Moloney and Siloto, 2004), which in addition facilitates easy
purification of the protein (as discussed later under cost of
downstream processing). Besides, proteins can be targeted to
membrane surfaces and protected from cytosolic degradation without
necessarily passing through the ER lumen by fusing the C-terminalregion of a tail anchored (TA) protein (Maggio et al., 2007). Other
subcellular compartments like the protein-storing vacuoles are also
now being explored for accumulating recombinant protein, as it has
been observed in rice seed endosperm (Yang et al., 2003). Extracel-
lular proteolytic cleavage is another important factor for consider-
ation in plant-based production of pharmaceuticals (Komarnytsky
et al., 2006; De Muynck et al., 2009). Komarnytsky et al. (2006) were
able to achieve a threefold increase in expression of an antibody when
co-expressed with a secreted form of the Bowman–Birk serine
peptidase inhibitor than when co-expressed with a cytosolic form of
this inhibitor. The addition of gelatin as a substitution substrate for
peptidases was also found to increase antibody levels to as high as
300% in tobacco rhizosecretion (Drake et al., 2003). In addition,
suspension cells culture media formulations that are rich in peptidase
inhibitor might provide safe in vitro environments for human IgG,
especially in tobacco. Better still, it would be worthwhile to develop
extracellular peptidase-free host plants or to engineer antibodies
displaying higher resistance to peptidases while maintaining their
activity (De Muynck et al., 2010).
3.2. The glycosylation challenge
Glycosylation is the covalent linkage of sugar moieties to proteins,
in order to enhance their folding, biological activity, solubility and
bioavailability (Liénard et al., 2007). In plant, glycosylation occurs in
the secretory pathway in the ER and the Golgi apparatus. However,
there are differences in the glycosylation patterns between the plants
and animals, with respect to N-glycan composition. Plants add α(1,3)
fucose and β(1,2) xylose residues to the N-glycan of their glycopro-
teins, whereas mammals add α(1,6) fucose moieties, glucose and
sialic acid residues to the N-glycan. Hence, to prevent the problem of
immunogenicity and allergic reactions that these differences could
potentially cause, when plant-derived therapeutic animal proteins are
administered to humans (Krapp et al., 2003), there is need to engineer
the plant to perform authentic human N-glycosylation. There are a
number of strategies that have been used to modify the N-
glycosylation pattern in the plants (Gomord et al., 2010). These
include the fusion of the ER-retention signal KDEL, which restricted
glycosylation of plant-derived antibodies to only high mannose-type
N-glycan (Floss et al., 2009), even though, however, such antibodies
with high mannose N-glycan have been reported previously to be
unstable after injection into mouse (Mainieri et al., 2004). Other
strategies that have been used include generation of knock-out
mutant lines in Arabidopsis and a moss plant, Physcomitrella patens,
that synthesize complex N-glycans lacking immunogenic xylose and
fucose epitope (Koprivova et al., 2004; Kang et al., 2008), and
modulation of the xylosylated and fucosylated glycan levels, using
RNA-interference (Sourrouille et al., 2008), as well as co-expression of
an RNA-interference construct with the therapeutic protein (Cox et al.,
2006). Also, the knock-in strategy, which involves the expression of a
hybrid enzyme obtained through domain fusion of the CST domain of
human β-1,4-galactosyltransferase I with β-1,2-xylosyltransferase of
Arabidopsis, was shown to cause high-level galactosylation of N-
glycans and sharp decrease in the level of N-glycans with xylose and
fucose moieties (Vézina et al., 2009). Moreover, synthesis of sialic acid
in plant and sialylation of plant-expressed protein has also been
reported (Castilho et al., 2010). Hence, it is clear that glycosylation
engineering is effective in adapting plant-made antibodies (De
Muynck et al., 2010), thus expanding the possibilities for the
production of optimally glycosylated proteins with enhanced biolog-
ical activities for use as human therapeutics (Loos et al., 2010).
3.3. Choice of suitable host plants
The choice of suitable host for deploying the molecular farming
technology is crucial for its overall success. In fact, though subtle, this
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recombinant protein production. Hence, economic consideration is
the key issue in choosing suitable host plants for molecular farming.
The important economic factors include total biomass yield, storage
properties (facilities), ease of transportation, value of the recombinant
protein itself, set-up costs, scale-up and maintenance costs, costs of
containment, availability of labor, land area required, length of
production cycle, costs of downstream processing and edibility
(Fischer et al., 2004; Schillberg et al., 2005). The suitable host should,
in addition to economic consideration, be amenable to transformation
and regeneration. Hence, the most suitable host plant for a particular
recombinant protein has to be determined empirically, based on these
highlighted factors, as there is no single perfect system thus far
(Schillberg et al., 2005).
In addition to being highly amenable to transformation and
regeneration, tobacco also combines most of these economic
advantages, such as high biomass yield, high scale-up capacity, non-
food/non-feed status (providing containment of transgenic material
from contaminating food and feed chain), well-established transfor-
mation protocols, all-year round growth and harvesting, and
availability of large scale infrastructure for processing (Biemelt and
Sonnewald, 2005; Fischer et al., 2004; Stoger et al., 2005a), which
explains why it is most preferred for molecular farming of
pharmaceutically relevant proteins including antibodies, vaccines
and immunomodulatory molecules such as cytokines (De Muynck
et al., 2010; Tremblay et al., 2010); many of which are at various
stages of development and even commercialization, as in the case of
CaroRX™, which is being used for preventing tooth decay (Ma et al.,
1998). However, tobacco (except cultivar “81V9, Menassa et al.,
2001), contains high amounts of toxic compounds, nicotine and other
alkaloids which have to be removed during purification process.
Besides, finding a beneficial use for tobacco in place of smoking
(which has been banned in public places in most of the developed
countries and nowadays in some developing countries) and providing
an alternative source of income for tobacco farmers through PMF do
not seem to appeal to the existing negative public sentiment against
tobacco in the United Kingdom, for instance (Milne, 2008). However,
the negative perception of tobacco with respect to its beneficial use
might not be an issue, especially when the PMF proteins are not for
human consumptions (e.g. for topical applications) and their
production are carried out in closed containment facilities, as such
tobacco-based production might still maintain its relevance for a long
time to come, just as the public comes to term with the fact that this
plant can as well be an indirect life-saver. Nevertheless, in the
meantime, alternative leafy crops like alfalfa and lettuce are now
being explored as suitable hosts for molecular farming (Rosales-
Mendoza et al., 2010). Leafy crops, however, generally have a
common problem of instability of the expressed proteins, which
necessitate that leaves have to be desiccated, or frozen or processed
immediately after harvest (Fischer et al., 2004). Additionally,
expression in vegetative organs, such as the leaf could affect growth
and development of the particular plant.
Seed-based expression seems to be more ideal in this respect, in
that, not only does it not affect the growth and development of the
plant but it does not need to be frozen or dried or processed
immediately, as accumulation of protein in the seed offers protection
against proteolytic digestion, as such it allows long-term storage at
ambient temperature without the protein losing its activity (Stoger
et al., 2002; Nochi et al., 2007). Additionally, seed-based expression
platforms are most competitive in applications that require large
volume of recombinant proteins per annum (Faye and Gomord,
2010). Moreover, the seed-based system allows oral delivery of
vaccine antigens or pharmaceutical proteins for immunization,
immunotherapy, and treatment of diseases (Lamphear et al., 2002;
Takagi et al., 2005). In this regard, the cereal seeds especially rice and
maize are gaining prominence. Maize has many advantages such ashaving the highest biomass yield among food crops, ease of
transformation, and ease of scale-up (Ramessar et al., 2008a), which
explains why Prodigene Inc. preferred to use maize for the
commercial production of the first recombinant protein, avidin
(Hood et al., 1997) and bovine trypsin (Woodard et al., 2003). The
Pharma-Planta Consortium has also adopted it for the production of a
HIV microbicide (Ramessar et al., 2008b). In addition to sharing many
of the advantages of maize, rice is a self-pollinating plant, as such it
would have a lower risk of unintended gene flow, which is why
Ventria Bioscience has pioneered the production of two rice-derived
proteins, human lactoferrin and lysozyme, which have received
regulatory approvals, and have already been marketed (http://
www.ventria.com, Boothe et al., 2010; Huang et al., 2008; Lau and
Sun, 2009). Similarly, ORF genetics Inc. is now exploiting the great
potential of cereal seeds (barley) in producing their two commercial
products ISOkine™ and DERMOkine™ human-like growth factors,
thereby bypassing the use of bacterial or animal cell systems (http://
www.orfgenetics.com/, Faye and Gomord, 2010). The advantage of
exceptionally high protein content (20–40%) in legume seeds,
coupled with the self-pollinating status of soybean and pea has
made them candidate platform for accumulating recombinant
proteins. Soybean, in particular, has been explored for its efficacy to
express a humanized antibody against herpes simplex virus, bovine
casein, and a human growth hormone (Philip et al., 2001; Russell
et al., 2005; Zeitlin et al., 2009). Soybean was also used to express a
functional hypotensive peptide, which reduced the systolic blood
pressures of model mice (Yamada et al., 2008).
3.3.1. Cost of downstream processing
The cost of downstream processing of plant-derived recombinant
proteins is believed to account for about 80% of the total production
costs (Buonaguro and Butler-Ransohoff, 2010; Kusnadi et al., 1998);
as such it has been given its well-deserved attention with respect to
devising strategies to reduce it to the barest minimum. However,
using watery tissues such as tomatoes as the production systems has
been advanced to have the potential of lowering this cost, as it is
easier to extract from them than dry tissue like cereals (Schillberg
et al., 2005; Yano et al., 2010). Additionally, with respect to biosafety
concern on containment of the transgenic plants, tomatoes also
appear attractive as a host crop, because they are grown in
greenhouses. Nowadays, the oil bodies in certain oilseed crops like
safflower and rape seeds are now being exploited to ease recombinant
protein purification, and minimizing the downstream costs, by using
the oleosin fusion technology developed by SemBioSys Genetics
(http://www.sembiosys.com/). The strategy involves targeting the
recombinant protein to the seed of the oilseed crops as a fusion with
oleosin, hence simplifying the extraction of the fusion proteins from
the oil bodies and the release of the recombinant protein from its
fusion partner, for example in the case of accumulating and purifying
biologically active human insulin, Apolipoprotein AI (Milano) and
human growth hormone in safflower (Boothe et al., 2010; Nykiforuk
et al., 2006; Nykiforuk et al., 2010).
It is envisaged that the advantage of lower cost of production
might facilitate the participation of less developed countries in
pharmaceutical production in plants (Paul and Ma, 2010). There are
indeed several plant-derived recombinant proteins that were earlier
thought to be delivered as edible vaccines, which can be eaten directly
as fruits (tomatoes, banana) and vegetables (lettuce, carrot), thus
eliminating the need for any processing, hence no processing costs
(Mason et al., 2002). Banana in particular, was being touted as a
candidate host fruit crop for producing edible vaccine, especially for
the developing countries, as there would not be need for long-
distance transport and satisfying cooling requirements, since it is
widely grown in these countries (Biemelt and Sonnewald, 2005).
Additional advantages of banana are that of high digestibility and
palatability, as such they were earlier gaining public acceptance for
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potatoes for oral vaccine production had also generated interest
because they can be eaten raw or with just little processing. Potatoes,
like seeds, have the advantage of product stability due to the
specialized molecular environment in the tuber (Sparrow et al.,
2007). Several clinical trials of potato tuber-derived antigens have
been successful (Streatfield and Howard, 2003; Walmsley and
Arntzen, 2003), however, for the crop to be acceptable for use in
oral vaccine administration, there must be some degree of processing,
cooking, in order to destroy the endotoxins; a process that will
degrade the thermolabile protein products (Sparrow et al., 2007). Due
to ethical issues however, the consequential shift in research focus
toward the development of heat stable oral vaccines (Rybicki, 2009) is
now giving way to the production of plant-derived vaccines that
would still be processed further, formulated in a reproducible way
and given under supervision so as to ensure reproducible effects
(Rybicki, 2010).
As a result of the demand for high containment of transgenic
plants these days, safer and more cost-effective alternative plant-
based expression platforms are now being sought after, including
Physcomitrella patens, a moss and green algae, such as Chlamydomonas
reinhardtii. These two expression systems combine the intrinsic
advantage of being amenable to cultivation in bioreactors under
controlled conditions (Decker and Reski, 2004, 2008; Franklin and
Mayfield, 2004; Hohe et al., 2002; Tran et al., 2009) with the
possibility of secreting of recombinant proteins into the medium
(thus reducing the extraction and purification costs) (Mayfield and
Franklin, 2005), and with a simple transformation procedure and
shorter production cycle (Leon-Banares et al., 2004; Schaefer, 2002).
Physcomitrella has even been engineered to produce a strain that does
not add immunogenic β(1,2) xylose and α(1,3) fucose (Koprivova
et al., 2004), thus eliminating the concern about non-human
glycosylation, which is the reason for its adoption by German biotech
company, Greenovation Biotech as their production platform, and
uniquely branded as bryotechnology (http://www.greenovation.
com). Other example of plant-based expression system is the Lemna
plant, which has very high rate of biomass accumulation per unit
of time; doubling in size every 24–48 h (Liénard et al., 2007) and
are amenable to transformation and metabolic engineering, for the
expression of humanize N-glycans (Cox et al., 2006). Besides, there
has been recent revisiting of the rhizosecretion technology, a
hydroponic production system, as a suitable, cost-effective production
system, which also combines the advantage of confined environments
with the flexibility of adding the hydroponic medium directly to a
chromatography column for affinity purification, thus allowing simple
and rapid production of high purity recombinant protein products
(Drake et al., 2009). Three affinity tags commonly used include His6,
StrepII and Tandem Affinity Purification (TAP) tag (Terpe, 2003). An
elastin-like polypeptide tag has also been optimized for expression
and purification of recombinant proteins in plants (Conley et al.,
2009).
4. Overview of plant-derived recombinant proteins
4.1. Plant-derived vaccine antigens
A vaccine is an antigenic preparation that improves immunity
against a particular disease. The development of non-replicating viral
protein subunit was inspired by the intrinsic risks involved in
producing large amounts of vaccines through the traditional method
of using live attenuated or inactivated viruses (Varsani et al., 2003).
Hence, there was a shift to the current production of subunit vaccines
in bacteria, yeast, and mammalian cells. However, these conventional
expression systems have some peculiar problems. As such, the idea of
using plants as a platform for production of vaccines was borne out of
its numerous potential advantages over the existing ones, includingthe potential for large scale production, production costs reduction
and oral delivery option (Streatfield and Howard, 2003; Pujol et al.,
2005; Buonaguro and Butler-Ransohoff, 2010) as well as being
potential hosts for the production of glycosylated subunit vaccines
(Bosch and Schots, 2010). Several vaccines have been expressed in
plants, since the first plant-derived vaccine-relevant protein was
reported 20 years ago (Rybicki (2009; Tiwari et al., 2009). These
include the hepatitis B surface antigen, which has been expressed in
transgenic potatoes (Richter et al., 2000), in tomato (He et al., 2008),
in banana (Kumar et al., 2005) and in tobacco cell suspension culture
(Sojikul et al., 2003), the heat labile enterotoxin B subunit (LTB) of
Escherichia coli, has ben expressed in potato tubers (Lauterslager et al.,
2001), in maize seed (Chikwamba et al., 2002), in tobacco (Rosales-
Mendoza et al., 2009), and in soybean (Moravec et al., 2007).
The cholera toxin B subunit (CTB) of Vibrio cholera has been
expressed in several crops, including tobacco, tomato and rice (Daniell
et al., 2001a; Mishra et al., 2006; Nochi et al., 2007), several plant-
made vaccines for veterinary purposes including, avian influenza,
Newcastle disease, foot-and-mouth disease and enterotoxigenic
Escherichia coli have been expressed in the plant (Lentz et al., 2010;
Ling et al., 2010), and the Hemagglutinin protein of rinderpest has
been expressed in pigeon pea and peanut (Satyavathi et al., 2003).
Others include the L1 protein of human papillomavirus types 11 and
16 (Biemelt et al., 2003; Maclean et al., 2007; Giorgi et al., 2010), the
Norwalk virus capsid protein (Mason et al., 1996), the Hemagglutinin
protein from measles virus (Marquet-Blouin et al., 2003) and the
H5N1 pandemic vaccine candidate (D'Aoust et al., 2010), all of which
have been expressed in one or two of the following plants: tobacco,
potato and carrots. Also worthy of note, is the US Defense
Department-sponsored research and development of various bio-
defense vaccines against anthrax, ricin, plague and haemorrhagic
fever virus (Hull et al., 2005; Koya et al., 2005; Santi et al., 2006; Mett
et al., 2007).
Plant-produced antigens have been reported to induce immune
responses, conferring protection against challenge in mouse model
systems (Satyavathi et al., 2003; Streatfield and Howard, 2003). Oral
administration of several plant-produced antigens has been reported
to induce protective immune response in humans (Thanavala et al,
2005; McCormick et al., 2008) and mice (Daniell et al., 2001b;
Tregoning et al., 2005). However, about 100-fold of the vaccine
delivered by injection is required for oral administion (Streatfield and
Howard, 2003). Notably, Franconi et al. (2006) andMassa et al. (2007)
reported that immunization with plant-produced antigen protected
the injected mice from tumour challenge with an E7-expressing
tumour cell line, while Koya et al. (2005) reported that mice injected
and immunized with chloroplast-derived anthrax protective antigen
survived anthrax lethal toxin challenge. Also the Gal/GalNAc lectin of
Entamoeba histolyticawas found to be highly immunogenic in injected
mice (Chebolu and Daniell, 2007). There are several plant-produced
vaccine candidates, which are at different stages of clinical trials, as
summarized in Table 1. It should be noted that the first veterinary
vaccine, the NDV vaccine for poultry developed by Dow AgroSciences,
has been approved by the US Department of Agriculture (USDA)
(http://www.dowagro.com/animalhealth). As such, the plant-based
production processes are able to compete with conventional methods,
breaking the limits of current standard production technologies and
reaching new frontiers for the plant-based production of pharmaceu-
tical-grade proteins (Buonaguro and Butler-Ransohoff, 2010).
4.2. Plant-derived antibodies
Antibodies or immunoglobulins (IgGs) are serum proteins that
bind to target molecules with high specificity and are widely used for
prevention, detection and treatment of diseases. Up till recently,
monoclonal antibodies were only being used to treat diseases such as
arthritis, cancer, immune and inflammatory diseases. Recombinant
Table 1
Plant-derived pharmaceuticals in clinical stages of development or on market. Information from Basaran and Rodríguez-Cerezo (2008), Kaiser (2008), Key et al. (2008), Spök et al.
(2008), Sharma and Sharma (2009), Lau and Sun (2009), Obembe (2010), Faye and Gomord (2010). Updated from company websites.
Product Disease Plant Clinical trial status Company Source: URL/academic
Vaccines
Hepatitis B antigen
(HBsAg)
Hepatitis B Lettuce
Potato
Phase I
Phase II
Thomas Jefferson University, USA
Arizona State University
Streatfield, 2006
Fusion proteins, including
epitopes from rabies
Rabies Spinach Phase I completed Thomas Jefferson University, USA www.labome.org/expert/usa/.../
hilary-koprowski-233492.html
Cancer vaccine Non-Hodgkin's
lymphoma
Tobacco Phase II Large Scale Biologya, USA http://www.gmo-safety.eu/article/483.
pharma-plants-status-report.html
Vibrio cholerae Cholera Potato Phase I Arizona State University Tacket, 2005
Heat-labile toxin B subunit
of Escherichia coli
Diarrhea Maize
Potato
Phase I
Phase I
ProdiGeneb, USA
Arizona State University
Tacket, 2005
Capsid protein Norwalk
virus
Diarrhea Potato,
Tomato
Phase I Arizona State University Khalsa et al., 2004
Antigen Feline parvovirus
(Dogs)
Tobacco Advanced Large Scale Biologya, USA http://www.lsbc.com
Antigen Papilloma virus
(Rabbit)
Tobacco Early Large Scale Biologya, USA http://www.lsbc.com
HN protein of Newcastle
disease virus
Newcastle disease
(Poultry)
Tobacco suspension
cells
USDA Approved Dow Agro Sciences,
USA
http://www.dowagro.com/
animalhealth
Viral vaccine mixture Diseases of horses,
dogs, and birds
Tobacco suspension
cells
Phase I Dow Agro Sciences,
USA
http://www.dowagro.com/
animalhealth
Poultry vaccine Coccidiosis infection Canola Phase II Guardian Biosciences, Canada Basaran and Rodríguez-Cerezo (2008)
Gastroenteritis virus
(TGEV) capsid protein
Piglet gastroenteritis Maize Phase I ProdiGeneb, USA Basaran and Rodríguez-Cerezo (2008)
H5N1 vaccine candidate H5N1 pandemic
influenza
Tobacco Phase I Medicago, USA http://www.medicago.com
Antibodies
CaroRX Dental caries Tobacco EU approved as
medical advice
Planet Biotechnology, USA http://www.planetbiotechnology.com/
DoxoRX Side-effects of
cancer therapy
Tobacco Phase I completed Planet Biotechnology, USA http://www.planetbiotechnology.com/
RhinoRX Common cold Tobacco Phase I completed Planet Biotechnology, USA http://www.planetbiotechnology.com/
Fv antibodies Non-Hodgkin's
lymphoma
Tobacco Phase I Large Scale Biology, USA http://www.lsbc.coma
IgG (ICAM1) Common cold Tobacco Phase I Planet Biotechnology, USA http://www.planetbiotechnology.com/
Antibody against hepatitis B Vaccine purification Tobacco On market CIGB, Cuba Kaiser, 2008
Therapeutic human proteins
Gastric lipase, Merispase® Cystic fibrosis Maize On market Meristem Therapeutics France http://www.meristem-therapeutics.
com
α-Galactosidase Fabry disease Tobacco Phase I Planet Biotechnology, USA http://www.planetbiotechnology.com/
Lactoferon™
(α-interferon)
Hepatitis B and C Duckweed Phase II Biolex, USA http://www.biolex.com/
Fibrinolytic drug
(thrombolytic drug)
Blood clot Duckweed Phase I Biolex, USA http://www.biolex.com/
Human glucocerebrosidase
(prGCD)
Gaucher ‘s disease Carrot suspension
cells
Awaiting USDA's
approval
Protalix Biotherapeutics,
Israel
http://www.protalix.com/
glucocerebrosidase.html
Insulin Diabetes Safflower Phase III SemBioSys, Canada http://www.sembiosys.com/
Apolipoprotein Cardiovascular Safflower Phase I SemBioSys, Canada http://www.sembiosys.com/
Nutraceuticals
ISOkine™ , DERMOkine™ Human growth factor Barley On market ORF Genetics http://www.orfgenetics.com/
Human intrinsic factor,
Coban
Vitamin B12 deficiency Arabidopsis On market Cobento Biotech AS http://www.cobento.dk/
default.asp?id=76
Human lactoferrin Anti-infection,
anti-inflammatory
Rice Advanced, on market
as fine chemical
Ventria, USA http://www.ventriabio.com/
Human lysozyme Anti-infection,
anti-inflammatory
Rice Advanced, on market
as fine chemical
Ventria, USA http://www.ventria.com/
Immunosphere™ Food additive for
shrimps
Safflower Marketing expected
for 2010
SemBioSys, Canada http://www.sembiosys.com/
a LSBC filed bankruptcy in 2006.
b Prodigene has winded up activity.
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against pathogens, as such are potentiated as promising alternatives
to combat infectious diseases, especially in the face of increasing
microbial resistance to antibiotics and the emergence of new
pathogens (Casadevall, 1998). Though, there is increasing market
demand, however, the prevailing high cost of production is prevent-
ing their successful introduction into the health market, as therapy of
infectious diseases. These opposing factors, thus, call for cost-effectivealternatives for large scale production (Stoger et al., 2005b), as bulk
production in the established production system- the mammalian
cells, presently poses difficult challenge, with respect to the
complexity of the product and the different processes involved, such
as post-translational modifications and proteolysis. Plants do not only
provide cheaper production platforms, as plant-derived antibodies
would cost just 0.1–1% of the production cost of mammalian culture
and 2–10% of microbial systems (Chen et al., 2005), but also can also
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as such can be engineered for the production of diverse tailor-made
pharmaceutical proteins. Since the first recombinant antibodies were
expressed in plants in 1989 (Hiatt et al., 1989), different moieties
ranging from single chain Fv fragments (ScFvs, which contain the
variable regions of the heavy and light chains joined by a flexible
peptide linker) to Fab fragments (assembled light chains and
shortened heavy chains), small immune proteins (SIP), IgGs, and
chimeric secretory IgA and single-domain antibodies have been
expressed as well (Ismaili et al., 2007; Xu et al., 2007).
There are two main approaches that are being employed to
produce biologically active whole antibodies in plants. The first is
cross-pollination of individually transformed plants expressing light
or heavy chains, resulting in high yield which reaches 1 to 5% of total
plant protein (Hiatt et al., 1989; Ma et al., 1994). The second approach
involves co-transformation of the heavy and light chain genes on a
single- (During et al., 1990), two- (Villani et al., 2008) or more
expression cassettes (Nicholson et al., 2005). One of such plant-
derived antibodies, a secretory antibody against a surface antigen of
Streptococcus mutans was actually found to be as effective as the
original mouse IgG, in protecting against S. mutans colonization on
teeth, (Ma et al., 1998). The antibody has since been developed further
by Planet Biotechnology, Inc. into a clinical product, CaroRX™, which
has recently received EU approval to be used as medical advice for the
prevention of oral bacterial infection that contributes to dental caries
(Kaiser, 2008). Recently, a HIV-specific monoclonal antibody, which
was produced in maize seeds, was found to be as active as its Chinese
hamster ovary-derived counterpart, in terms of antigen-binding
activity (Ramessar et al., 2008a, 2008b). There are five different
plant-derived monoclonal antibodies presently being tested in the
clinical trials, as listed in Table 1. The sixth one, Avicidin was
withdrawn from the trials because of several side effects suffered by
the participants, even though it showed promising results against
advanced colon and prostate cancer (Ma et al., 2005). The first plant-
made scFv monoclonal antibody, used in the production of a
recombinant hepatitis B virus vaccine, has been commercialized in
Cuba (Pujol et al., 2005).
4.3. Therapeutic and nutraceutical proteins
The first therapeutic human protein to be expressed in plants was
a human growth hormone (Barta et al., 1986). In 1990, human serum
albumin, which is normally isolated from blood, was produced in
transgenic tobacco and potato for the first time (Sijmons et al., 1990).
Since then, several human proteins have been expressed in the plants.
These include epidermal growth factor (Wirth et al., 2004; Bai et al.,
2007), α-, β- and γ-interferons, which are used in treating hepatitis B
and C (Sadhu, and Reddy, 2003; Zhu et al., 2004; Arlen et al., 2007),
erythropoietin, which promote red blood cell production (Weise et al.,
2007; Musa et al., 2009), interleukin, which is used in treating Crohn's
disease (Elias-Lopez et al., 2008; Fujiwara et al., 2010), insulin, which
is used for treating diabetes (Nykiforuk et al., 2006), human
glucocerebrosidase, which is used for the treatment of Gaucher's
disease in genetically engineered carrotcells (Shaaltiel et al., 2007)
and several others. Also contained in Table 1 is the list of some of these
therapeutics, which are at various stages of clinical trials or at the
verge of being commercialized.
Antimicrobial nutraceutics, such as human lactoferrin and lyso-
zymes, have now been successfully produced in several crops (Huang
et al., 2008; Stefanova et al., 2008), and now commercially available,
only as fine chemicals (Table 1). Cobento Biotechnology, Denmark has
just recently received approval for its Arabidopsis-derived human
intrinsic factor (Key et al., 2008), which is to be used against vitamin
B12 deficiency and now commercially available as Coban (Sharma and
Sharma, 2009). Other nutraceutical products at various stages of
development are listed in Table 1.4.4. Non-pharmaceutical plant-derived proteins
The non-pharmaceutical plant-derived proteins or industrial
proteins, most of which are enzymes, including avidin, trypsin,
aprotinin, β-glucuronidase, peroxidase, laccase, cellulase and others
listed in Basaran and Rodríguez-Cerezo (2008) are now on the
market. The molecular farming of cell-wall deconstructing enzymes
such as cellulases, hemicellulases, xylanases and ligninases, in
particular, holds great promise for the biofuel industry, with respect
to the production of cellulosic ethanol (Sticklen, 2008; Mei et al.,
2009; Chatterjee et al., 2010), which was estimated to have the
potential of reducing greenhouse gas emissions by 100% compared to
gasoline (Fulton et al., 2004). Other non-hydrolytic proteins, such as
the cell wall disrupting carbohydrate binding modules of cell wall
deconstructing enzymes, and the cell wall loosening proteins, the
expansins, which have been implicated in enhancing the efficiency of
wall degradation by disrupting the different polysaccharide networks,
thereby allowing increase accessibility of the hydrolytic enzymes to
the substrate, have been previously demonstrated to alter cell wall
structure (Obembe et al., 2007a; Obembe et al., 2007b), and as such
have been recommended as candidate PMF proteins for the biofuel
industry (Obembe, 2010).
Other potential non-pharmaceutical plant-derived technical pro-
teins that are being explored and optimized for production include
biodegradable plastic-like compounds such as polyhydroxyalkanoate
(PHA) copolymers, Poly (3-hydroxybutyrate) (PHB) and cyanophycin
(Conrad, 2005; Matsumoto et al., 2009). It should be noted that thus
far, only few plant-derived pharmaceuticals have been approved, and
fewer still are commercially available, majorly because of biosafety
concerns and stringent governmental regulations with respect to field
trials, good manufacturing practice (GMP) standards and pre-clinical
toxicity testing.
5. Biosafety and regulatory issues
The general public concern about the potential health and
environmental risks associated with the PMF crops (not the products)
is being viewed at two levels; in that, not only are they engineered to
accumulate all sorts of proteins withmedicinal properties at very high
concentration, which may affect the host plants (Badri et al., 2009),
but also that their biologically active products are meant to elicit
physiological responses in humans and in animals (Spök, 2007; Spök
et al., 2008). Additionally, there are specific concerns, including the
risks of (i) co-mingling with food/feed crops and the resultant
economic risks to farmers and food industry, (ii) transgenes spread by
pollen, seed or fruit dispersal, (iii) unintended exposures to non-
target organisms, particularly birds, insects and soil microorganisms,
and (iv) horizontal gene transfer by asexual means (Commandeur
et al., 2003; Andow et al., 2004; Wisner, 2005).
Like for the GM food and feed crops, several regulations are being
developed, to increase the biosafety of the plant bioreactors, even
though, one knows that, there is no fool-proof system, as there might
be some elements of human errors and natural accidents, which are
beyond control.
5.1. Problem of co-mingling and contamination of the food/feed chain
The problem of co-mingling and contamination of the food/feed
chain is being prevented by the use of non-food and non-feed crops,
such as tobacco, lemna, Arabidopsis, microalgae or mosses (Cox et al.,
2006; Decker and Reski, 2008; Franklin and Mayfield, 2004; Tremblay
et al., 2010). However, when it is desirable to use food or feed crops, as
in the case of monoclonal antibodies and oral vaccines, strict physical
agronomic confinement and containment strategies are being applied
to avoid co-mingling. These include growing in small restricted and
isolated areas, remote from the agricultural crops to avoid mechanical
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et al., 2008), crop destruction and post-planting field cleaning,
planting at different periods to ensure harvesting at different periods
from other crops intended for use as food and feed (Spök, 2007), the
use of non-commercial varieties or plant containing visible marks
(Biemelt and Sonnewald, 2005), prohibition of trade in seeds and
viable plants (Spök et al., 2008), and the use of dedicated machineries
and facilities (US Department of Agriculture, 2006). As it is very
difficult to avoid admixtures of GM and non-GM crops, even with
confinement (USDA/APHIS, 2006b), threshold limits of accidental
contaminations are now being introduced, for example in Europe,
0.5% presence of GM in non-GM or feed is allowed (European
Parliament, 2003) and for non hazardous, non-pharmaceutical plant-
made products, the threshold limit of contamination is set at 0.9%
(Spök, 2007).
5.2. The problem of gene spread and unintended exposures
The biosafety strategies being used to address the problem of gene
spread and unintended exposures of the plant bioreactors, irrespective of
the status (food or non-food crop), include the use of closed isolated
containment facilities, such as greenhouses (Menassa et al., 2001),
glasshouses, hydroponics (Commandeur et al., 2003; Drake et al., 2009)
and plant cell suspension cultures (www.protalix.com) (Franconi et al.,
2010; Plasson et al., 2009), the use of biological containment, such as self-
pollinating species (cleistogamous lines) (Leflon et al., 2009), chloroplast
transformation (Svab and Maliga, 2007), the use of male-sterile
transgenic plants (Gils et al., 2008), the use of sexually incompatible
crop with wild relatives, the production of non-germinating seeds or
non-sprouting tubers/bulbs (through the use of a technology known as
“Genetic use restriction technologies (GURTs”) (Hills et al., 2007). Other
strategies being pursued to minimize the gene spread and exposure to
other organisms include cytoplasmic male sterility (Chase, 2006),
engineered parthenocarpy and apomixis (Rotino et al., 2005; Sandhu
et al., 2009), transgene excision (Gidoni et al., 2008), engineering the
plants for organ- or tissue-specific expression of the transgene (for
example in the fruits) (Heet al., 2008), and theuseof induciblepromoters
that respond to external stimuli or chemicals can be exploited to regulate
gene expression at some point after harvest (Corrado and Karali, 2009),
especially as it hasbeen shownthat certainplant-derived insecticidesand
biopharmaceutical proteins can remain stable in the soil for a long period
(Basaran and Rodríguez-Cerezo, 2008). Another strategy being deployed
for curtailing the effect of gene spread is transgenic mitigation, which
does not by itself prevent transgene flow from transgenic crops to
nontransgenic crops or wild relatives, but ‘mitigates’ the effects of such
gene flow, i.e. its goal is to prevent the establishment of the transgene in
volunteer populations or in populations of wild relatives if hybridization
can occur (Gressel and Valverde, 2009).
5.3. Risk of horizontal gene transfer
The risk of horizontal gene transfer from plants to microbes,
especially in the case of using antibiotic resistance genes, is generally
believed to be extremely low, as there has been no report of such
incidence to date. More so, it is widely known that plants, including
the edible ones, naturally harbor loads of bacteria with antibiotic-
resistant genes (Nielsen et al., 1998).
It should be noted that most of the aforementioned biosafety
strategies have been motivated by regulatory policies and guidelines of
the different countries involved in the research, development and
industrial applications of the PMF technologies. However, it has been
admitted that the enforcement of the regulations is still leaky, as it is
difficult to monitor all the different stages of development and
processing of the plant-derived products, as such there exists some
laxities in the level of compliance on the part of the operators, which go
undetected by the regulatory agencies. The civil society now perceivesthe regulatory guidelines on GM crops in general as being relaxed or
compromised, which explains why some unapproved GM foods still
manage to find their ways to the dining tables in the US and most
unexpectedly in Europe. This calls for stricter compliance with good
manufacturing practice standards, all through the stages of develop-
ment, in order to ensure the delivery of clinical grade plant-derived
products.
6. Concluding remarks
No doubt the PMF industry is here to stay, considering the quantum
of advances thathavebeenmade in thepastdecade alone. Though, there
had been somedisappointing incidence at somepoints, which led to the
lull in the industry, and even to the folding up of someof the big players,
including Prodigene, we do share the same sentiment with Kaiser
(2008) that exciting times are now returning to the industry, as a
numberof newplayers are nowpickingup interest andentering into the
field. One such player is the multinational company Bayer, which is
collaborating with a number of biotech companies and has recently
bought the German company, Icon Genetics that developed the
MagnICON technology. Alsoworthmentioning, is the research program
of the EU-funded Pharma-Planta consortium, which is devoted to
developing and ultimately producing recombinant pharmaceuticals in
plants, for humanitarian purpose! With their recent successful
development of a cost-effective seed-based production technology for
a vaginal protectionmicrobicide to prevent heterosexual HIV transmis-
sion, the stage in now set for the deployment of the same technology to
produce other therapeutic bio-molecules on a large scale, which could
be made more widely available and cheaper than presently possible
(Ramessar et al., 2008a, 2008b). In 2009, another International Research
Group (consisting of Universities, Research Institutes and new biotech
companies) successfully accumulated over 1 g/kg of a red algal protein,
a lectin known as griffithsin (GRFT-P) in Nicotiana benthamiana leaves
(O'Keefe et al., 2009). This protein, in addition to exhibiting broad-
spectrum activity against awide range of HIV strains and similar viruses
causing sexually transmitted infections, represents themost potent HIV
entry inhibitor to date (Zeitlin et al., 2009; O'Keefe et al., 2009). Having
met all the requirements to be used as a microbicide, GRFT-P is now
being validated as a candidate protein microbicide for clinical trials
(O'Keefe et al., 2009) and it is hoped that the recent results on efficacy
dilution of candidate microbicide (Mâsse et al., 2009) would be useful
for successful trials. It is envisioned that all of these developments in
PMFwould begin to attract newer stakeholders to join in, especially for
clinical developmentof large volumebiologics,which are presently very
expensive to manufacture with the conventional manufacturing
practice. Most of all, the overall prospects of plant-based molecular
farming industry will depend on improved public perception of the
technology and the products, especially as the industry improves its
level of compliance with the regulations, and as there are many
successful clinical trials and approvals of the first set of these plant-
derived human pharmaceuticals. It is also envisioned that the public
perception would be all the more positive with the recent European
Union's preparation for “pharmed drugs” (Gilbert, 2009; Rybicki, 2010).
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